Loading...
Market
How will Chai-1 perform in a major AI competition by December 31, 2024?
2
Resolution / Starting Odds
Outperforms all models • 25%
Outperforms AlphaFold3 but not ESM3 • 25%
Outperforms ESM3 but not AlphaFold3 • 25%
Does not outperform either • 25%
Results from a major AI or computational biology competition
Story
Chai Discovery Raises $30M, Unveils Chai-1 Rivaling AlphaFold3 for Drug Discovery
Sep 9, 2024, 04:46 PM
Chai Discovery, an artificial intelligence biology startup founded six months ago, has raised nearly $30 million from Thrive Capital and OpenAI to advance AI-driven drug discovery. The company has unveiled Chai-1, a multimodal molecular structure prediction model that rivals AlphaFold3 and ESM3 in performance. Chai-1, developed in just four months, is open-source and includes inference code, weights, and a web interface. The model is designed to accelerate drug discovery by predicting molecular structures from sequences, showcasing significant potential in the field. Co-founders Josh and Jack Dent, who have been Neo Scholars since 2017, lead the initiative.
View original story
Similar markets
NeurIPS • 25%
ICML • 25%
AAAI • 25%
Other • 25%
Meta's Llama 3.1-70B • 25%
OpenAI's GPT-4 • 25%
Google's Bard • 25%
Other • 25%
OpenAI's O1 model • 25%
GPT-4 • 25%
Gemini • 25%
Anthropic's Claude • 25%
Winning a Kaggle competition • 25%
Winning a NeurIPS competition • 25%
Winning an ImageNet challenge • 25%
Other major competition • 25%
Gold medal at 2025 IMO • 25%
Winning a Kaggle competition • 25%
Breakthrough in protein folding • 25%
Other • 25%
Gemini 2.0 Flash Thinking • 25%
OpenAI's o1 • 25%
Microsoft's AI Model • 25%
Other • 25%
Significantly better • 25%
Slightly better • 25%
On par • 25%
Worse • 25%
Google's Gemini • 25%
OpenAI's GPT • 25%
Microsoft's Azure AI • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
